and meta-analyses (13) (14) (15) (16) (17) (18) . Some novel loci were found by GWA studies performed in Asian populations (19, 20) . Renal allograft recipients are at high risk for developing diabetes mellitus caused by a number of factors.
Therefore, we investigated whether variations in the recently identified diabetes-susceptibility genes (TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, FTO, WFS1, JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, NOTCH2, and KCNQ1) are associated with the development of PTDM in a Korean renal allograft recipient cohort (13) (14) (15) (16) (17) (18) .
PATIENTS AND METHODS

Subjects and Measurements
A total of 820 unrelated renal transplant recipients were recruited from patients at the Severance Hospital Transplantation Center, Yonsei University Health System. PTDM was diagnosed 1 year posttransplantation according to the International Consensus Guidelines for the diagnosis and management of PTDM (21) (22) (23) . Patients who started antidiabetic medication after transplantation and continued to take the medication were also included in the PTDM group.
Patients were eligible to participate in the study if they were the recipients of a kidney allograft with no other history of organ transplantation and were followed up for at least 1 year. Individuals with no previous diagnosis of diabetes and a recorded pretransplantation fasting plasma glucose (FPG) level less than 5.5 mmol/L were included. Patients were excluded from the study if they had a history of diabetes, severe metabolic disorder (e.g., hyperthyroidism, hypothyroidism, Cushing syndrome, acromegaly, or pheochromocytoma), infectious disease (e.g., tuberculosis, pneumonia, or human immunodeficiency virus infection), or a recorded FPG level greater than 5.5 mmol/L before transplantation. After our screening criteria were applied, a total of 589 unrelated renal allograft recipients were enrolled in the study.
Medical histories were obtained during the initial visit, and family histories of diabetes were based on first-degree relatives only. Height and weight measurements were taken at the time of transplantation, as well as 3 and 6 months after transplantation. Blood samples were collected after an overnight fast. The FPG level was determined using an enzymatic colorimetric assay. The immunosuppressive regimens consisted of calcineurin inhibitors and glucocorticoids, and their administration schedules were similar to that reported previously (11, 12) . The average daily steroid dose was calculated at the time of study. The internal review board of Severance Hospital approved the study protocol, and all subjects were provided with adequate information about the nature of the study and gave informed consent.
Gene and Single Nucleotide Polymorphisms Selection
Six genes (SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO) identified through recent GWA studies, as well as six novel genes identified through recent metaanalyses of GWA studies (JAZF1, CDC123/CAMK1D, TSPAN8, THADA, ADAMTS9, and NOTCH2) (18) , plus WFS1 (24) and TCF7L2, were selected for this study. For the rs7903146 in TCF7L2, we extended our previous study cohort (11) to 589 patients and subsequently analyzed the potential association with PTDM. Because rs7754840 and rs10946398 in CDKAL1 were in complete linkage (DЈϭ1, r 2 ϭ1) in 200 of our samples and in the study by Palmer et al. (25) , we only analyzed rs10946398 in full samples. Regarding WFS1, among the four single nucleotide polymorphisms (SNPs; rs734312, rs752854, rs6446482, and rs10010131) initially reported to be associated with type 2 diabetes mellitus (T2DM) (24), we only genotyped WFS1 rs734312, because a pilot genotyping in 88 of our samples showed that the minor allele frequency (MAF) of WFS1 rs752854 was 0, WFS1 rs6446482 was 0.011, and WFS1 rs10010131 was 0. We excluded THADA in genetic analysis because of its extremely low MAF (THADA rs7578597 MAFϭ0.0032) and NOTCH2 caused by a high rate of genotyping error (18.93%).
Genotyping and Quality Control
Genomic DNA was isolated from peripheral blood lymphocytes. Genotyping was performed using a TaqMan SNP genotyping assay system (Applied Biosystems, Foster City, CA). The assay mix IDs were C29347861_10 for TCF7L2 rs7903146, C2684958_1 for SLC30A8 rs13266634 R325W, C11214581_10 for HHEX rs1111875, C31982553_10 for HHEX rs7923837, C477786_10 for HHEX rs5015480, C29246232_10 for CDKAL1 rs10946398, C31288917_10 for CDKN2A/B rs10811661, C2165199_10 for IGF2BP2 rs4402960, C2031259_10 for FTO rs8050136, C2401729_10 for WFS rs734312 H611R, C7601116_20 for JAZF1 rs864745, C26360618_10 for CDC123/CMK1D rs12779790, C121473_10 for TSPAN8 rs7961581, C26129590_10 for ADAMTS9 rs4607103, and C1188816_10 for NOTCH2 rs10923931. The KCNQ1 rs2237892 genotype was assayed by a single-base primer extension assay using an ABI PRISM SNaPShot Multiplex Kit (ABI, Foster City, CA), according to manufacturer's instructions. The primer sequences were as follows: forward primer, 5Ј-TCCCAGGTGTGGCTAAG-3Ј; reverse primer, 5Ј-CAGCTGAGCACAAGGCTA-3Ј; and genotyping primer, 5Ј-GGAGCTGTCACAGGACTTTGCCACC-3Ј. A total of 48 (7.6%) duplicate samples and negative controls were included to ensure the accuracy of the genotyping, and 100% of the duplicates replicated the original genotype. The genotype success rate was 99.36% for rs7903146 in TCF7L2, 99.36% for rs13266634 in SLC30A8, 99.36% for all three SNPs in HHEX, 95.38% for rs10946398 in CDKAL1, 99.36% for rs7754840 in CDKN2A/B, 99.36% for rs4402960 in IGF2BP2, 98.41% for rs8050136 in FTO, 99.36% for rs734312 in WFS1, 97.61% for rs864745 in JAZF1, 97.29% for rs12779790 in CDC123/CAMK1D, 98.09% for rs7961581 TSPAN8, 99.04% for rs4607103 ADAMTS, and 98.8% for KCNQ1 rs2237892.
Statistical Analyses
The allele and genotype frequencies were compared between the non-PTDM and PTDM groups using a Pearson's 2 test (Table 1 ). All continuous variables are expressed as the meanϮSD. A Student's t test was used to compare the continuous variables, and the 2 test was used to compare the categorical variables between the PTDM and non-PTDM groups. The differences between the PTDM and non-PTDM groups in genotype distribution were analyzed using a logistic regression analysis. The Mantel-Haenszel 2 test was used to evaluate the trend of diabetes risk with an increased number of risk alleles. A Cox proportional hazard model was used to identify risk factors for PTDM development, as well as to calculate the adjusted hazard ratio and 95% confidence intervals. The combined effect of multiple SNPs on the risk of PTDM was determined using logistic regression after categorizing the patients into groups according to the number of the risk alleles that they carried with the associated SNPs (TCF7L2 rs7903146, SLC30A8 rs13266634, HHEX rs1111875, HHEX rs7923837, HHEX rs5015480, CDKAL1 rs10946398, CDKN2A/B rs10811661, and KCNQ1 rs2237892). The P values less than 0.05 were considered statistically significant. Statistical analyses were performed using the SPSS package for Windows (version 12.0; SPSS, Chicago, IL).
RESULTS
Clinical Characteristics of PTDM Patients
The overall incidence of PTDM in this study population was 24.6% (145 of 589). The clinical parameters of the transplant recipients are listed in Table 2 . Patients in the PTDM group were older than those in the non-PTDM group. The median follow-up length was 124 months (10.3 years). PTDM patients were followed up longer than non-PTDM patients. The initial body weight was not significantly different between the two groups, but weight gain differed significantly between the two groups during the first 6 months after transplantation (Pϭ0.022). Although the baseline FPG level was not significantly different between the two groups, PTDM patients exhibited a higher FPG level than non-PTDM patients 3 months after transplantation, despite antidiabetes treatment. Patients who used tacrolimus as an immunosuppressive agent had a higher incidence of PTDM (Pϭ0.032).
Genotype Distribution and Association Between Genotype and PTDM
Among the 17 SNPs examined, eight SNPs in the six loci were nominally associated with PTDM (TCF7L2 rs7903146, Pϭ0.016; SLC30A8 rs13266634, Pϭ0.003; HHEX rs1111875, Pϭ0.007; HHEX rs7923837, Pϭ0.014; HHEX rs5015480, Pϭ0.003; CDKAL1 rs10946398, Pϭ0.008; CDKN2A/B rs10811661, Pϭ0.039; and KCNQ1 rs2237892, Pϭ0.009). The eight SNPs were associated with PTDM in an allele-specific manner, with odds ratios ranging from 1.33 to 2.32. The major risk alleles were SLC30A8 rs13266634, CDKAL1 rs10946398, CDKN2A/B rs10811661, JAZF1 rs864745, and ADAMTS9 rs4607103 (Table 1) .
Multivariable Cox Proportional Hazard Regression Analysis of Risk Factors Associated With PTDM
Independent risk factors for PTDM were identified using multiple Cox proportional hazard regressions. We included age, gender, baseline FPG, weight gain, type of immunosuppressant, and genotype as covariates in the regression model, because all of these were associated with PTDM in the univariate association tests ( Table 2 ). As given in Table 3 , the eight SNPs remained significant after adjustment for age, gender, body weight gain, and type of immunosuppressant. The heterozygous hazard ratios were not statistically significant 
DISCUSSION
Recent GWA studies of T2DM have identified several novel SNPs in type 2 diabetes susceptibility genes (13, 15, 16, 19, 20) . Likewise, the six novel loci were identified through a recent meta-analysis of GWA studies (18) . In addition, the KCNQ1 locus has been found to be associated with diabetes by GWA studies performed in Asian populations (19, 20) . In this study, we performed association analyses between these loci and PTDM to confirm the results of previous GWA studies in renal allograft recipients. In our analysis, the eight SNPs in six genes were found to be significantly associated with PTDM (TCF7L2 rs7903146, SLC30A8 rs13266634, HHEX [rs1111875, rs7923837, and rs5015480], CDKAL1 rs10946398, CDKN2A/B rs10943698, and KCNQ1 rs2237892).
We have previously reported that common genetic variations in the TCF7L2 and SLC30A8 loci contribute to PTDM development (11, 12) , independent of steroid dose and the type of calcineurin inhibitors. In this study, we extended our previous cohort (11) to examine other loci. Similar to our previous study (26) , we diagnosed PTDM 1 year posttransplantation and included the patients who were followed up for at least 1 year after transplantation.
In examining TCF7L2 and SLC30A8, we observed the same result as our previous reports (11, 12) . Additionally, SNPs in the HHEX locus have been reproducibly associated with T2DM in Japanese populations (27, 28) . An analysis of our genotype data revealed that the r 2 values were less than 0.33 for rs1111875, rs7923837, and rs5015480 in HHEX, and we did not perform a haplotype analysis. We confirmed that all the three HHEX SNPs were associated with PTDM, similar to the Japanese populations (27, 28) . For rs1111875, the risk allele G has been shown to be a minor allele in Asian subjects, including our group (27, 28) , whereas the G allele has been shown to be a major allele in European populations (13, 15, 17) . Thus, this gene might have a stronger impact on the development of PTDM in Asian populations.
CDKAL1 rs10946398 and CDKN2A/B rs10811661 also displayed a nominal association with T2DM in Asian populations (29 -32) . CDKAL1 and CDKN2A/B are believed to play a role in cell-cycle control in beta cells. We did not analyze rs7754840, because CDKAL1 rs10946398 and rs7754840 were in complete linkage (DЈϭ1, r 2 ϭ1), consistent with the results reported by Palmer et al. (25) .
In contrast to two Japanese studies (29, 30) , rs4402960 in IGF2BP2 was not associated with PTDM in this study. This may have been resulted from a lack of statistical power in this study because of the relatively small sample size. However, although several reports have demonstrated a negative association in Japanese populations (29) , there is only a marginal association in non-Japanese Asian populations (31) , and no association in two GWA studies (13, 14) .
In regard to KCNQ1, which was recently identified as a susceptibility gene in Eastern Asian populations (20) , an association was observed between PTDM and the rs2237892 genotype, similar to our previous report (32) . KCNQ1 is expressed in the pancreas and is a subunit of the voltage-gated Kϩ channel (KvLQT1). Modulation of the membrane potential by KvLQT1 could be a possible mechanism of sensitivity to the development of PTDM.
Although there was no significant association between the FTO rs8050136 genotype and PTDM in our study, there was a tendency for the subjects with the risk A allele to show a somewhat greater body mass index at baseline and 3 months after transplantation (data not shown), which is consistent with a report from a white population (33) .
In regard to WFS1, we genotyped only WFS1 rs734312 among the four SNPs (rs734312, rs752854, rs6446482, and rs10010131) that were initially reported to be associated with T2DM (24) because of the extremely small MAF for the other SNPs in our cohort. We were unable to observe a significant association between WFS1 rs734312 and PTDM.
Currently, multiple polymorphisms in the human leukocyte antigen, the vitamin D receptor (10), interleukin-6 promoter (34), glucokinase (8), TCF7L2 (11) , and SLC30A8 (12) , have been reported to be susceptibility loci for PTDM. Further, most of these genes are believed to play a role in insulin secretion than insulin resistance. We have previously reported that defects in insulin secretion play a more crucial role than increased insulin resistance in the pathogenesis of PTDM (11, 12, 26, 35) . Moreover, most of the PTDM-associated genes identified in this study are believed to be involved in insulin secretion.
A limitation of this study was that oral glucose tolerance tests were not routinely performed before transplantation and preexisting diabetes or impaired glucose tolerance could have led to an overestimation of PTDM. Another limitation was the relatively small sample size, which led to a relatively low statistical power (20%-60%) and precluded the study of gene-gene interactions.
Nonetheless, our study benefited from its longitudinal physiologic and environmental data, as well as from specific phenotype-related research. Studies with more patients will be required to test the more modest effects that have been published previously. Most of the genetic variations confirmed in this study are reported to be associated with insulin secretion, but because of the lack of oral glucose-tolerance testing, we could not confirm the function and expression of these variants.
In conclusion, some of T2DM-associated genetic variants discovered in recent GWA studies are also associated with PTDM. In particular, genetic variations in TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B and KCNQ1 are associated with PTDM in Korea.
